David De Leeuw
Chairman of the Board
David E. De Leeuw is a founding partner of Lion Chemical Partners, a private equity firm focused on investing in premier businesses operating in the chemical and materials industries. Mr. De Leeuw founded Lion Chemical Partners with his brother Pete De Leeuw in 2014 to acquire, manage and eventually monetize chemicals and materials businesses. Prior to Lion Chemical Partners, David and Pete founded Lion Chemical Capital in 2001, and since the Firm’s founding, Lion Chemical has invested and/or advised on transactions in the chemical industry valued at over $4 billion and have earned excellent returns for their investors. Mr. De Leeuw has more than 40 years of investment experience in various sectors including consumer goods and services and financial services.
Mr. De Leeuw serves as Chairman of Lion Cao Asset Management, an investment management firm which he co-founded in 2005, that focuses on private equity, direct investments, co-investments and funds.
Prior to establishing Lion Chemical Partners and Lion Cao Asset Management, Mr. De Leeuw was a founding partner at McCown De Leeuw & Co., which raised more than $1.2 billion in four funds and invested over $1 billion in 40 leveraged platform acquisitions and over 100 add-ons. Mr. De Leeuw led or played a key role in numerous financings for McCown De Leeuw including IPOs, mezzanine debt, bonds, and private financings, as well as acquisitions, divestitures, and secondary offerings over a 20-year period.
Prior to founding MDC in 1984, Mr. De Leeuw led the leveraged acquisitions group at Citibank, and was previously at W.R. Grace & Co., and Paine Webber in New York and Tokyo. Mr. De Leeuw, currently and in the past, has served on more than 25 Boards (with several listed on the NYSE or NASDAQ) since 1984, often as Chairman or Vice Chairman. He is, and has been, an active personal investor in numerous start-ups, late stage Venture, Private Equity transactions as well as Private Equity Funds and Hedge Funds. He is currently Chairman of Medality Medical and Health Settlement, a funding source for personal injury lawsuits. Mr. De Leeuw received an MBA from Columbia University, and a BA in History from Lafayette College. He is currently an Advisory Board Member of Columbia’s Private Equity Program, and has served as a visiting lecturer at Columbia Business School and Harvard College. He is on the Board of Trustees at Guild Hall. In 2013, Mr. De Leeuw and his brother, Pete De Leeuw, were awarded the Chemical Marketing & Economics Group Leadership Award for Distinction in Private Equity.
Phillip Chan, MD/PhD
Dr. Chan is the CEO and President of CytoSorbents Corporation (CTSO-NASDAQ), a leader in critical care immunotherapy, specifically leading in the prevention and treatment of life-threatening inflammation using the patented CytoSorb Blood Purification device. Prior to CytoSorbents, he led healthcare and life science investments as a Partner for the NJTC Venture Fund. In that role, he was responsible for numerous investments in therapeutics, medical devices and diagnostics. Phil also co-founded Andrew Technologies as an early and lead investor. He received Board-certification in internal medicine, completing his residency at Harvard Medical School at the Beth Israel Deaconess Medical Center. He received his MD/PhD from Yale University School of Medicine and his BS in Cell and Molecular Biology from Cornell University. Dr. Chan is also a member of Medality’s Medical and Scientific Committee.
Ed, and the teams he led, have improved medical care for countless individuals, worldwide. Over a span of 30 years in the medical device field, he has focused on the advancement of global healthcare via applied innovation. He was formally Senior Director – Diabetes Care Division of Becton Dickinson and has over 15 years of business experience in diabetes care and surgical devices. He has led a number of large multi-national business teams, formed two new business units and was responsible for development and implementation of strategies that led to industry leading growth and share-of-category positions for a number of multi-billion-dollar enterprises.
Mark S. Andrew
Founder and Chief Scientific Officer (CSO)
Dr Andrew is the Founder and Chief Scientific Officer of Medality Medical, LLC. He is the co-inventor of Tissue Liquefaction Technology® (TLT). Medality Medical’s’ HydraSolve® is the second clinical application of TLT, the first being the AquaLase® Liquefaction Device, a small-incision cataract removal technology on Alcon’s premier cataract machine, the INFINITI® Vision System, used routinely in more than 50 countries. Dr Andrew, a Fellow of the American Academy of Ophthalmology, is a board-certified ophthalmologist with more than 25 years’ experience. He received his medical degree from Jefferson Medical College (Sidney Kimmel Medical College) in Philadelphia, PA, and served his residency at Hahnemann University Hospital in Philadelphia. His scientific background includes basic science research in biochemistry, endocrinology, and immunology, as well as research in fluid dynamics at: the National Eye Institute of the National Institutes of Health (NIH), Drexel University School of Biomedical Engineering, Jefferson Medical College (Sidney Kimmel Medical College), Wills Eye Hospital and the Penn State Health Milton S. Hershey Medical Center. Dr Andrew holds 10 issued US patents, 27 issued foreign patents, with more pending. Dr. Andrew’s inventions have led to 6 FDA clearances, 25 peer-reviewed journal articles and numerous surgical textbook citations.
Sid Prakash, MD, is a diagnostic radiologist and serial entrepreneur based in New York City.
Currently, he owns several successful medical practices which he founded and built over the past several years: Precision Accelerad, an outpatient imaging practice located in Manhattan and the Bronx, NY; AMDS Radiology, an outpatient imaging center in Staten Island, NY; and Specialized Imaging Doctor, a teleradiology company which has contracted with over 20 imaging centers, predominantly in the tri-state area. He has a laser-like focus on providing superior concierge-level service for his patients as well as in creating sustained collaborative relationships with medical providers.
Previously, he was Chairman of the Department of Radiology and the Chief Information Officer at North General Hospital, a Mount Sinai-affiliated hospital in Manhattan, NY. He graduated with highest honors and a B.A. degree in biology with concentration in biophysics from Washington University in 1997. Subsequently, he obtained his Doctorate of Medicine degree at the University of Missouri-Columbia. He became Board-Certified in Diagnostic Radiology after graduating from his medical residency at Long Island Jewish Medical Center in 2007.
Recently, he is focusing on private equity investments in healthcare companies to advance medical care in multiple disciplines, leveraging his understanding of medical practices and hospital environments to help increase financial growth and brand recognition.
Peter Gerald Malone
Peter Gerald Malone MA LLB (Gerald) is, by profession, a Scottish lawyer and was a UK politician from 1983 to 1997.
Mr. Malone was elected as Member of Parliament (MP) for Aberdeen South (1983-87) and served as a Whip in Margaret Thatcher’s government. In 1992 he was elected MP for Winchester, was appointed Deputy Chairman of the Conservative Party until 1994, then Minister of State for Health in John Major’s administration.
Since 1997, when he left politics, Mr. Malone has served on the boards of a number of UK funds and healthcare companies. In 2001 he joined the board of Aberdeen Asia-Pacific Income Fund (FAX), a US closed end mutual fund, becoming Chairman in 2005. He also chairs additional open and closed end US and Canadian funds managed by Aberdeen Standard, is a board member of the Mutual Fund Directors Forum in Washington DC and a director of Bionik Laboratories, a North American healthcare robotics company.
Additionally, Mr. Malone has extensive experience in journalism – having been Scottish Editor of The Sunday Times (1987 -1991) and Deputy Editor of The European (1997 – 1999) – of broadcasting, and consultancy in public affairs – www.brexRisk.com. He currently writes on American culture and politics for Reaction Life, a UK online publication.
Brian V. Murray
Chief Financial Officer, Board Member
Mr. Murray established BV Murray & Co. Inc., a boutique investment bank in 1996 after 17 years at Bear Stearns in the corporate finance department where he was a Senior Managing Director. Prior to joining Bear Stearns in 1978, he was a partner at HC Wainwright & Co, an institutional Wall Street research firm. Over his career, Mr. Murray has obtained extensive worldwide experience in mergers and acquisitions, valuations and public and private debt and equity of offerings. Mr. Murray holds a B.S. degree in Economics from Villanova University, an MBA with honors (majoring in finance and international business) from the University of Chicago and is a Chartered Financial Analyst (“CFA”).
Mr. Coelho is a Partner based in the San Diego office. He has led StepStone’s efforts in venture capital and growth equity since the inception of the Firm and focuses on fund investments, secondaries and direct/co-investments in technology, healthcare and services.
Mr. Coelho spent his entire career prior to StepStone advising and investing in emerging growth companies. Prior to StepStone, he was at ATEL Capital Group, a venture debt and asset-based lender in San Francisco. Mr. Coelho also served as a venture capital advisor to Unigestion, an alternative asset manager based in Geneva, and managed direct venture capital and private equity investments on behalf of Plantagenet Capital Management in San Francisco. Prior to this, Mr. Coelho was in the Technology Investment Banking Group at Piper Jaffray & Co. in Menlo Park, where he executed over $4 billion of equity offering and M&A transactions in the software, communications and computing sectors. He began his career at Wilson Sonsini Goodrich & Rosati in Palo Alto.
Mr. Coelho received his BS and MBA from the Haas School of Business at the University of California, Berkeley.